Lunit is entering a full-scale monetization phase for its medical AI business developed in collaboration with Microsoft. The company developed a Foundation Model Service (FMS) that enables medical institutions to optimize Lunit's AI models for their hospital environments using their own data. In May 2026, Lunit signed MOUs with major Korean hospitals including National Health Insurance Service Ilsan Hospital and Severance Hospital to collaborate on AI transformation across hospital treatment, operations, and administration.
Cyborg Score Rationale
Lunit demonstrates strong clinical validation, proven commercial traction, and strategic partnerships. The company has filed for FDA clearance of multiple products, achieved KOSDAQ public listing, and secured partnerships with Microsoft and leading global hospitals. However, competitive intensity in medical AI imaging and regulatory execution risks prevent a higher score.
Top Insights
Lunit launched its Microsoft-co-developed platform in Q2 2026 with upfront and milestone-based revenue expected in 2026
The company submitted an FDA 510(k) for Lunit INSIGHT Risk, a mammography-based breast cancer risk prediction model, with clearance expected in 2026
Lunit presented six AI studies at AACR 2026 highlighting advancements in AI-driven biomarker development and tumor microenvironment analysis
Lunit achieved 173% CAGR revenue growth from 2019–2025 and raised $122M while unlisted, becoming top 12% of KOSDAQ-listed companies by market position
Named Competitors
Screenpoint Medical — AI mammography detection and risk assessment
Barco Healthcare — AI-powered medical imaging analysis and clinical decision support software
Philips Healthcare AI — AI-enabled medical imaging diagnostics and cancer detection solutions
Subtle Medical — AI medical imaging enhancement and diagnostic support software
Tempus AI — AI-powered oncology diagnostics and precision medicine platform
Recent Developments
(April 2026) Lunit CTO announced Microsoft-co-developed medical AI platform launch in Q2 2026 with revenue expected in 2026
(May 2026) Signed MOU with National Health Insurance Service Ilsan Hospital to deploy AI across hospital treatment, operations, and administration
(May 2026) Partnered with Severance Hospital to jointly develop and clinically deploy medical AI based on medical foundation model
(December 2025) Submitted FDA 510(k) premarket notification for Lunit INSIGHT Risk mammography-based breast cancer risk prediction model
Open the full interactive Lunit report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.